HP-004 (Hepius Therapeutics)

HP-004 (Hepius Therapeutics): sourced facts only. name: "HP-004 specifically binds ALPP/ALPPL2 but not the related isozymes ALPI or ALPL, minimizing potential on-target off-tumor liability." [DOI:10.1158/1538-7445.am2026-4401]; target: "HP-004 specifically binds ALPP/ALPPL2 but not the related isozymes ALPI or ALPL, minimizing potential on-target off-tumor liability." [DOI:10.1158/1538-7445.am2026-4401]; developer: "Hepius Therapeutics, Suzhou, China." [DOI:10.1158/1538-7445.am2026-4401]; modality: "HP-004 is a novel ADC targeting both ALPP and ALPPL2, with high selectivity and enhanced internalization efficiency." [DOI:10.1158/1538-7445.am2026-4401]; stage: "In the ALPP/ALPPL2-positive NCI-H1651 xenograft lung cancer model, HP-004 administration achieved near-complete tumor regression at 3 mg/kg (Q2W X4), with complete tumor regression in 6 of 8 mice, demonstrating a robust antitumor activity." [DOI:10.1158/1538-7445.am2026-4401]